ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
1,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
1,4,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
3,1,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
4,1,Cystitis haemorrhagic,Bladder infections and inflammations,Bladder and bladder neck disorders (excl calculi),Renal,N
5,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
5,2,Renal tubular necrosis,Renal vascular and ischaemic conditions,Renal disorders (excl nephropathies),Renal,N
6,1,Deafness,Hearing losses,Hearing disorders,Ear,N
7,1,Haemolytic anaemia,Anaemias haemolytic NEC,Haemolyses and related conditions,Blood,N
7,2,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
8,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
8,2,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
8,3,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
9,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
10,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
11,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
11,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
12,1,Activated partial thromboplastin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
12,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
13,1,Superficial vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
14,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
14,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
14,3,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
14,4,Tachypnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
15,1,Thrombophlebitis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
16,1,Thrombophlebitis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
17,1,Thrombophlebitis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
18,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
18,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
18,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
19,1,Haemolytic anaemia,Anaemias haemolytic NEC,Haemolyses and related conditions,Blood,N
20,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
21,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
21,2,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
22,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
23,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
23,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
24,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
25,1,Prothrombin level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
26,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
27,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
27,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
28,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
29,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
30,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
30,2,Prothrombin level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
30,3,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
31,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
32,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
33,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
34,1,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
35,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
36,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
36,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
36,3,Urinary retention,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
37,1,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
38,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
39,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
39,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
39,3,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
39,4,Monocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
39,5,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
40,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
41,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
42,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
43,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
44,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
45,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
